In what could be a miracle improving and saving thousands of lives across the globe, Russia’s mRNA-based vaccine Enteromix has displayed 100% efficacy and safety in clinical trials.The treatment which targets and destroys cancer cells while efficiently shrinking large tumours, now awaits final approval from the Ministry of Health before being made available to the public, RT India reported.Enteromix was developed using cutting-edge technology, similar to the one used in COID-19 vaccines. It works by training the immune system to recognize and eliminate cancer cells. Additionally, it is personalized for every individual patient.Interestingly, unlike chemotherapy or radiation, there were no serious side effects of the vaccine and patients tolerated it well.
Image credits: X
Earlier, it was revealed that Russia had begun clinical trials of the new EnteroMix oncolytic vaccine with 48 participating volunteers. The drug was developed by the country’s Ministry of Health’s National Medical Research Radiology Centre in collaboration with the Engelhardt Institute of Molecular Biology (EIMB) of the Russian Academy of Science (RAS).The start of the clinical trial was announced at the St. Petersburg International Economic Forum (SPIEF 2025), held from June 18 to 21 in northern Russia. The event, organized by the Roscongress agency under the Russian President’s office, showcased Russia’s progress in medical research and biotechnology.As per a report in MedPath, Enteromix makes use of four harmless viruses to attack and destroy cancerous tumours while also boosting the immune system to fight the disease. After going through several years of testing, it has shown effectiveness in slowing down growth and in some cases completely destroying the cancer.With the trials out of the way, the only remaining step is regulatory clearance. If approved, Enteromix could become the first personalized mRNA cancer vaccine available to the public.
